Paradigm Biopharmaceuticals Ltd (PAR):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Paradigm Biopharmaceuticals Ltd (PAR) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C9379
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:31
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:オーストラリア
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Paradigm Biopharmaceuticals Ltd (Paradigm Biopharma) is a biopharmaceutical company. The company focused on research and development of therapeutic products for human use. It offers pentosan polysulphate sodium (PPS) drugs for new orthopaedic and respiratory applications. Paradigm Biopharma offers drugs in the injectable and tablet forms for bone marrow edema, respiratory disease, alphaviral arthritis, orthopaedic, alphavirus, and respiratory diseases. The company’s other indications include treating the allergic inflammatory response in allergic rhinitis (AR). It also conducts a phase 2b clinical trial to investigate PPS in subjects with Bone Marrow Lesions (BMLs) and osteoarthritis (OA). Paradigm Biopharma is headquartered in Melbourne, Victoria, Australia.

Paradigm Biopharmaceuticals Ltd (PAR) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Paradigm Biopharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Paradigm Biopharmaceuticals Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Paradigm Biopharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Paradigm Biopharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Paradigm Biopharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Paradigm Biopharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deal Details 10
Licensing Agreements 10
Paradigm Biopharma Enters into Licensing Agreement with Griffith University 10
Equity Offering 11
Paradigm Biopharma Raises USD4.8 Million in Private Placement of Shares 11
Paradigm Biopharma to Raise USD0.8 Million in Share Purchase Plan 13
Paradigm BioPharma Raises USD7 Million in IPO of Shares 14
Acquisition 15
Xosoma Acquires C4M Pharma 15
Paradigm BioPharma Acquires Xosoma 16
Paradigm Biopharmaceuticals Ltd – Key Competitors 17
Paradigm Biopharmaceuticals Ltd – Key Employees 18
Paradigm Biopharmaceuticals Ltd – Locations And Subsidiaries 19
Head Office 19
Other Locations & Subsidiaries 19
Recent Developments 20
Financial Announcements 20
Jul 28, 2017: Paradigm Biopharmaceuticals: June Quarter Update 20
Other Significant Developments 22
Oct 31, 2018: Paradigm Biopharmaceuticals: September 2018 quarterly report 22
Jul 27, 2018: Paradigm Biopharmaceuticals: June 2018 quarterly report 24
Apr 30, 2018: Paradigm: March 2018 Quarterly Report 26
Oct 31, 2017: Paradigm Biopharmaceuticals: September 2017 Quarter Update 29
Appendix 31
Methodology 31
About GlobalData 31
Contact Us 31
Disclaimer 31

List of Tables
Paradigm Biopharmaceuticals Ltd, Pharmaceuticals & Healthcare, Key Facts, 2018 2
Paradigm Biopharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Paradigm Biopharmaceuticals Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Paradigm Biopharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Paradigm Biopharmaceuticals Ltd, Deals By Therapy Area, 2012 to YTD 2018 8
Paradigm Biopharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Paradigm Biopharma Enters into Licensing Agreement with Griffith University 10
Paradigm Biopharma Raises USD4.8 Million in Private Placement of Shares 11
Paradigm Biopharma to Raise USD0.8 Million in Share Purchase Plan 13
Paradigm BioPharma Raises USD7 Million in IPO of Shares 14
Xosoma Acquires C4M Pharma 15
Paradigm BioPharma Acquires Xosoma 16
Paradigm Biopharmaceuticals Ltd, Key Competitors 17
Paradigm Biopharmaceuticals Ltd, Key Employees 18
Paradigm Biopharmaceuticals Ltd, Subsidiaries 19

List of Figures
Paradigm Biopharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Paradigm Biopharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Paradigm Biopharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Paradigm Biopharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Paradigm Biopharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Paradigm Biopharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Paradigm Biopharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Paradigm Biopharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[Paradigm Biopharmaceuticals Ltd (PAR):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Groupe Le Duff S.A.(Foodservice):戦略・SWOT・企業財務分析
    Groupe Le Duff S.A.(Foodservice) - Strategy, SWOT and Corporate Finance Report Summary Groupe Le Duff S.A.(Foodservice) - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, produ …
  • G. Siempelkamp GmbH & Co KG:企業の戦略的SWOT分析
    G. Siempelkamp GmbH & Co KG - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major product …
  • Hamburg Commercial Bank:企業の戦略・SWOT・財務分析
    Hamburg Commercial Bank - Strategy, SWOT and Corporate Finance Report Summary Hamburg Commercial Bank - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • Saudi Arabian Mining Co:企業の戦略・SWOT・財務情報
    Saudi Arabian Mining Co - Strategy, SWOT and Corporate Finance Report Summary Saudi Arabian Mining Co - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • IMEXHS Ltd (IME):企業の財務・戦略的SWOT分析
    IMEXHS Ltd (IME) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Synopsys Inc (SNPS):企業の財務・戦略的SWOT分析
    Synopsys Inc (SNPS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and t …
  • Petro River Oil Corp (PTRC):石油・ガス:M&Aディール及び事業提携情報
    Summary Petro River Oil Corp (Petro River), formerly Gravis Oil Corp, is an oil and gas company that offers independent energy solutions. The company operates in the exploration and development of conventional oil and gas assets. It develops projects in Osage County, Oklahoma; Kern County, Californi …
  • OncoTherapy Science Inc (4564):医療機器:M&Aディール及び事業提携情報
    Summary OncoTherapy Science Inc (OncoTherapy) is a biotechnology company that discovers and develops antibody drugs for treating cancer. The company offers products under antibodies, cancer vaccines and small molecule drugs. It provides contract research services. OncoTherapy conducts research and d …
  • Nippon Chemi-Con Corporation (6997):企業の財務・戦略的SWOT分析
    Nippon Chemi-Con Corporation (6997) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • Bonavista Energy Corp (BNP):石油・ガス:M&Aディール及び事業提携情報
    Summary Bonavista Energy Corp (Bonavista) is an intermediate energy company, which acquires, explores for, develops and produces oil and natural gas from its assets in the provinces of Alberta, British Columbia and Saskatchewan. Its core operations are concentrated in the Glauconite and Falher plays …
  • Imperial Holdings Limited:企業のM&A・事業提携・投資動向
    Imperial Holdings Limited - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Imperial Holdings Limited Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisi …
  • Applus Services, S.A.:企業のM&A・事業提携・投資動向
    Applus Services, S.A. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Applus Services, S.A. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M …
  • ELITechGroup Inc:医療機器:M&Aディール及び事業提携情報
    Summary ELITechGroup Inc (ELITech) is a medical device company that manufactures and distributes in vitro diagnostic equipment and reagents. The company’s products portfolio includes clinical chemistry, cystic fibrosis, hematology, microbiology and molecular diagnostics. Its clinical chemistry produ …
  • University of California San Diego:医療機器:M&Aディール及び事業提携情報
    Summary University of California San Diego (UCSD), a subsidiary of University of California, is a public research university that offers education and research with a portfolio of undergraduate, graduate, postdoctoral and professional schools. It offers courses in various fields including arts and h …
  • Vital Therapies Inc (VTL):医療機器:M&Aディール及び事業提携情報
    Summary Vital Therapies Inc (Vital Therapies) is a biotechnology company that discovers, develops and commercialize cell-based therapies. The company’s product candidate includes ELAD system, a human-cell-based bio artificial liver treatment designed to allow the patient's own liver to regenerate or …
  • A-Sonic Aerospace Limited:企業の戦略・SWOT・財務分析
    A-Sonic Aerospace Limited - Strategy, SWOT and Corporate Finance Report Summary A-Sonic Aerospace Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • Marr S.P.A.:企業の戦略・SWOT・財務分析
    Marr S.P.A. - Strategy, SWOT and Corporate Finance Report Summary Marr S.P.A. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate act …
  • FLSmidth & Co. A/S:企業の戦略・SWOT・財務情報
    FLSmidth & Co. A/S - Strategy, SWOT and Corporate Finance Report Summary FLSmidth & Co. A/S - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • The Brookwood Partnership Ltd:企業の戦略・SWOT・財務分析
    The Brookwood Partnership Ltd - Strategy, SWOT and Corporate Finance Report Summary The Brookwood Partnership Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and …
  • Gordon Ramsay Holdings Limited:企業の戦略・SWOT・財務情報
    Gordon Ramsay Holdings Limited - Strategy, SWOT and Corporate Finance Report Summary Gordon Ramsay Holdings Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product a …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆